Vicor Technologies Establishes Captive Lease Program for Purchase of its PD2i Analyzer™
News Jan 24, 2011
David H. Fater, CEO of Vicor Technologies, Inc. has announced that Vicor has established a captive lease program with Coastal Leasing, Inc. to provide a financing option for purchase of its PD2i Analyzer™. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i® nonlinear algorithm and software.
Vicor is currently in the process of commercializing diagnostics that enable physicians to accurately risk stratify specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention.
"Our newly-established captive lease program with Coastal Leasing represents a true win/win. Purchasers of our PD2i Analyzer™ now have access to a financing option through an established, reputable provider of equipment lease financing options that enables them to securely payout their purchase should they wish to do so, and Vicor has immediate access to the revenue generated on financed purchases to further our growth initiatives," stated Mr. Fater.
Coastal Leasing, Inc., established in 1980, is a progressive, service-oriented provider of equipment lease financing to a wide spectrum of industries on a national basis. Based in Ft. Lauderdale, FL, Coastal Leasing funds transactions via a full range of financial products, including tax-oriented (true) leases, lease purchases (lease finance agreements), master lease lines, sale/leasebacks, and chattel mortgages/loan and security agreements.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
International Conference on Hepatology and Liver Diseases
Jun 10 - Jun 11, 2019